miR-509-3p alteration of YAP1/ECM axis (WP3967)

Homo sapiens

Summary of findings for miR-509-3p and the YAP1/ECM axis. Reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041955/ Collectively, the results suggest that miR-509-3p-mediated changes in levels of YAP1 and ECM genes impair migration, invasion, and spheroid formation and so may attenuate metastatic progression in advanced stage ovarian cancer. Further, results suggest that the direct downstream miR-509-3p target YAP1 is likely a critical driver of cellular migration and spheroid formation in ovarian cancers in which levels of YAP1 protein are high. Proteins on this pathway have targeted assays available via the [https://assays.cancer.gov/available_assays?wp_id=WP3967 CPTAC Assay Portal].


Kristina Hanspers and Friederike Ehrhart


last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.


Homo sapiens




Disease Ontology

ovarian cancer cancer

Pathway Ontology

Hippo signaling pathway cancer pathway


Label Type Compact URI Comment
BCAR1 GeneProduct ensembl:ENSG00000050820
EDNRA GeneProduct ensembl:ENSG00000151617
FN1 GeneProduct ensembl:ENSG00000115414
SPARC GeneProduct ensembl:ENSG00000113140
THBS2 GeneProduct ensembl:ENSG00000186340
GPC6 GeneProduct ensembl:ENSG00000183098
COL1A1 GeneProduct ensembl:ENSG00000108821
COL3A1 GeneProduct ensembl:ENSG00000168542
COL5A1 GeneProduct ensembl:ENSG00000130635
PBX3 GeneProduct ensembl:ENSG00000167081
TWIST1 GeneProduct ensembl:ENSG00000122691
SNAI2 GeneProduct ensembl:ENSG00000019549
YAP1 GeneProduct ensembl:ENSG00000137693
MIR509-3 GeneProduct hgnc.symbol:MIR509-3
YAP1 GeneProduct ensembl:ENSG00000137693
TEAD1 GeneProduct ensembl:ENSG00000187079
TEAD2 GeneProduct ensembl:ENSG00000074219
TEAD3 GeneProduct ensembl:ENSG00000007866
TEAD4 GeneProduct ensembl:ENSG00000197905


  1. miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Pan Y, Robertson G, Pedersen L, Lim E, Hernandez-Herrera A, Rowat AC, et al. Oncotarget. 2016 May 3;7(18):25930–48. PubMed Europe PMC Scholia